Bluejay Diagnostics
BJDX
3 hedge funds and large institutions have $267K invested in Bluejay Diagnostics in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.53% more ownership
Funds ownership: 0% → 0.53% (+0.53%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$98.3K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$98.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$98.3K |
Top Sellers
BJDX Hedge Fund Activity: Q4 2021 in Review
3 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Bluejay Diagnostics (BJDX) for Q4 2021, worth a combined $267K.
Buyers outnumbered sellers: 3 funds opened new BJDX positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $98.3K.
- 3 institutional investors held Bluejay Diagnostics (BJDX) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $267K of Bluejay Diagnostics stock for Q4 2021.
- 3 funds opened new Bluejay Diagnostics positions in Q4 2021 and 0 closed out, a net change of +3 holders.
- The largest Bluejay Diagnostics buyer in Q4 2021 was Jane Street, an estimated $98.3K added.
Based on aggregated 13F filings for Q4 2021.